A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) an dCD30-expressing Peripheral T-cell Lymphoma (PTCL) in Older Patients or Patients With Significant Comorbidities Ineligible for Standard Chemotherapy
- Pingali, S. Ravi (PI)
- Ganguly, Siddhartha (Key Personnel)
- Petkova, Jenny (Key Personnel)
- Rice, Lawrence (Key Personnel)
- Shah, Shilpan (Key Personnel)
Project: Clinical Trial